Recommendations for HER2 testing in the UK

Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E. and Lee, P.B. (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53(12), pp. 890-892.

[img]
Preview
Text
bartlettjclinpath5312.pdf

140kB

Publisher's URL: http://jcp.bmjjournals.com/cgi/content/full/53/12/890

Abstract

Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gusterson, Professor Barry and Cooke, Prof Timothy
Authors: Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E., and Lee, P.B.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RB Pathology
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Journal of Clinical Pathology
Publisher:BMJ Publishing Group Ltd.
ISSN:0021-9746
Copyright Holders:Copyright © 2001 by the Journal of Clinical Pathology and Association of Clinical Pathologists
First Published:First published in the Journal of Clinical Pathology 53(12):890-892
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record